{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,9,16]],"date-time":"2025-09-16T19:18:28Z","timestamp":1758050308138,"version":"3.44.0"},"reference-count":11,"publisher":"Elsevier BV","issue":"12","license":[{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,12,1]],"date-time":"2022-12-01T00:00:00Z","timestamp":1669852800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.fr","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Bulletin du Cancer"],"published-print":{"date-parts":[[2022,12]]},"DOI":"10.1016\/j.bulcan.2022.09.008","type":"journal-article","created":{"date-parts":[[2022,10,19]],"date-time":"2022-10-19T23:29:50Z","timestamp":1666222190000},"page":"1230-1231","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"title":["Nouvelle AMM\u00a0: le Relatlimab\/nivolumab en premi\u00e8re ligne de traitement des m\u00e9lanomes m\u00e9tastatiques avanc\u00e9s dont l\u2019expression tumorale de PD-L1\u00a0est inf\u00e9rieure \u00e0 1\u00a0%"],"prefix":"10.1016","volume":"109","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0924-7371","authenticated-orcid":false,"given":"Marie","family":"Boileau","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0935-3358","authenticated-orcid":false,"given":"Lise","family":"Boussemart","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.bulcan.2022.09.008_bib0060","unstructured":"INCA. Recommandations INCA et SFD: Patients atteints de m\u00e9lanome de stade III inop\u00e9rable ou de stade IV 2017."},{"key":"10.1016\/j.bulcan.2022.09.008_bib0065","article-title":"Les cancers en France","volume":"2017","author":"Rapport INCA: INCA","year":"2017","journal-title":"\u00e9dition"},{"key":"10.1016\/j.bulcan.2022.09.008_bib0070","article-title":"Survie attendue des patients atteints de cancers en France: \u00e9tat des lieux","volume":"58","author":"Mazeau-Woynar","year":"2010","journal-title":"Observation-Veille-Documentation D."},{"key":"10.1016\/j.bulcan.2022.09.008_bib0075","doi-asserted-by":"crossref","first-page":"1821","DOI":"10.1200\/PO.21.00084","article-title":"Positive association between location of melanoma, ultraviolet signature, tumor mutational burden, and response to Anti\u2013PD-1\u00a0therapy","author":"Dousset","year":"2021","journal-title":"JCO Precision Oncology"},{"key":"10.1016\/j.bulcan.2022.09.008_bib0080","doi-asserted-by":"crossref","first-page":"e21545","DOI":"10.1200\/JCO.2021.39.15_suppl.e21545","article-title":"Differential gradients of efficacy of immunotherapy according to the sun-exposure pattern of the site of occurrence of primary melanoma: a multicenter prospective cohort study (MELBASE)","volume":"39","author":"Russo","year":"2021","journal-title":"JCO"},{"key":"10.1016\/j.bulcan.2022.09.008_bib0085","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","article-title":"Five-year survival with combined nivolumab and ipilimumab in advanced melanoma","volume":"381","author":"Larkin","year":"2019","journal-title":"N Engl J Med"},{"key":"10.1016\/j.bulcan.2022.09.008_bib0090","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1056\/NEJMoa2109970","article-title":"Relatlimab and nivolumab versus nivolumab in untreated advanced melanoma","volume":"386","author":"Tawbi","year":"2022","journal-title":"N Engl J Med"},{"year":"2022","series-title":"Research C for DE and. FDA approves Opdualag for unresectable or metastatic melanoma","key":"10.1016\/j.bulcan.2022.09.008_bib0095"},{"key":"10.1016\/j.bulcan.2022.09.008_bib0100","unstructured":"EMA. Opdualag: Pending EC decision. European Medicines Agency 2022. https:\/\/www.ema.europa.eu\/en\/medicines\/human\/summaries-opinion\/opdualag.(accessed August 28, 2022)."},{"key":"10.1016\/j.bulcan.2022.09.008_bib0105","series-title":"Double-blind Study of adjuvant immunotherapy with nivolumab+relatlimab fixed-dose combination versus nivolumab monotherapy after complete resection of stage III-IV melanoma","article-title":"A Phase 3, Randomized","author":"Bristol-Myers Squibb","year":"2022"},{"key":"10.1016\/j.bulcan.2022.09.008_bib0055","doi-asserted-by":"crossref","first-page":"1668","DOI":"10.1056\/NEJMc2119768","article-title":"CTLA-4\u00a0blockade resistance after relatlimab and nivolumab","volume":"386","author":"Menzies","year":"2022","journal-title":"N Engl J Med"}],"container-title":["Bulletin du Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122003587?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0007455122003587?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,13]],"date-time":"2025-09-13T19:36:18Z","timestamp":1757792178000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0007455122003587"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,12]]},"references-count":11,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2022,12]]}},"alternative-id":["S0007455122003587"],"URL":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.09.008","relation":{},"ISSN":["0007-4551"],"issn-type":[{"type":"print","value":"0007-4551"}],"subject":[],"published":{"date-parts":[[2022,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Nouvelle AMM\u00a0: le Relatlimab\/nivolumab en premi\u00e8re ligne de traitement des m\u00e9lanomes m\u00e9tastatiques avanc\u00e9s dont l\u2019expression tumorale de PD-L1\u00a0est inf\u00e9rieure \u00e0 1\u00a0%","name":"articletitle","label":"Article Title"},{"value":"Bulletin du Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bulcan.2022.09.008","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 Soci\u00e9t\u00e9 Fran\u00e7aise du Cancer. Published by Elsevier Masson SAS. All rights reserved.","name":"copyright","label":"Copyright"}]}}